Kirin Holdings Company (2503) Investor presentation summary

Strategic vision and growth engines

• Aims to be a global leader in creating value across food, beverages, and pharmaceuticals, focusing on mental and physical well-being by 2035.

• Health Science established as a third growth engine through acquisitions like FANCL and Blackmores.

• Strategic direction is clearly defined, with improved profitability and stronger cash flow since 2019.

• Innovation across all business segments is prioritized to maintain customer preference and drive growth.

• Emphasis on co-creation with AI and a diverse, innovation-driven workforce.

Financial targets and value creation

• Targets high single-digit EPS growth and ROIC of at least 10%.

• Seeks to achieve a market cap of 3 trillion yen through EPS and PER expansion.

• Balanced profit portfolio across three core businesses to ensure resilience.

• Cash allocation focuses on growth investments, stable dividends, and share buybacks, with a progressive dividend policy.

• Divestment of Four Roses to optimize the portfolio and fund share buybacks, offsetting EPS impact.

Business portfolio and regional strategy

• Continuous review of the business portfolio to focus on areas leveraging group strengths for well-being.

• Health Science and Non-Alcoholic Beverages to increase EPS contribution, especially in Asia-Pacific.

• Direct sales expansion in China and Southeast Asia, and innovation-driven value creation in domestic and overseas markets.

• Pharmaceuticals to sustain growth through new launches and label expansions.

• Aim to build a distinctive product portfolio supporting mental and physical well-being.